Gentibio Announces $157M Series A Financing To Advance Engineered Regulatory T Cells As Transformative Therapeutics With Potential To Restore Immune Tolerance And Durably Treat Autoinflammation
Amount Raised
$157 Million
Round Type
Series A
CambridgeBiotechnologyHealth CareTherapeuticsDescription
GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, today announced it has closed on a Series A financing generating immediate proceeds of $157 million, led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, and Novartis Venture Fund, and Seattle Children's Research Institute. The company's unique platform aspires to functionally cure autoimmune, alloimmune, autoinflammatory, and allergic diseases using novel technologies that precisely redirect stable, potent engineered Tregs to tissues damaged by abnormal immune responses. GentiBio, leveraging its highly differentiated platform, is able to create multiple, tunable Treg phenotypes from more abundant autologous and allogeneic cell sources that can be manufactured at scale. GentiBio has raised $177 million since 2020 to transcend technical hurdles that have limited the potential of therapeutic Tregs.
Quick answer
GentiBio raised $157 Million in a Series A round, dated August 11, 2021. GentiBio is based in Cambridge, Massachusetts, United States.
- How much did GentiBio raise?
- GentiBio raised $157 Million in a Series A round on August 11, 2021.
- What does GentiBio do?
- GentiBio is a leading cell and gene therapy company specializing in engineered regulatory T cells (Tregs) programmed to treat autoimmune and inflammatory diseases.
- Where is GentiBio based and how big is it?
- GentiBio is based in Cambridge, Massachusetts, United States. Fundz records about 59 employees.
- Who are the decision-makers at GentiBio?
- Fundz holds 2 contacts at GentiBio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as GentiBio that raised within 45 days of this round, from Fundz verified event records.
- BioVaxys Technology Corp. raised $249K (Pre-Seed) on September 22, 2021.
- bluebird bio raised $75M on September 21, 2021.
- CytoDyn raised $2.9M (Seed) on September 16, 2021.
- BrainXell raised $13M on September 13, 2021.
- Whitehawk Therapeutics, Inc. raised $155M on September 10, 2021.
- bluebird bio raised $75M (Post-IPO Equity) on September 8, 2021.
Who to call at GentiBio, and when
A new round usually means GentiBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day GentiBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GentiBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GentiBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GentiBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansGentiBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.